LX-101 from Lirum Therapeutics Inc. is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor consisting of an IGF-1 variant coupled to a cytotoxic methotrexate payload. There are several aggressive cancer types of unmet need that have altered IGF-1R pathways and/or high IGF-1R expression, which correlates with poor prognosis.